The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antitubercular inhaled therapy: opportunities, progress and challenges
Abstract
Pulmonary tuberculosis remains the commonest form of this disease and the development of methods for delivering antitubercular drugs directly to the lungs via the respiratory route is a rational therapeutic goal. The obvious advantages of inhaled therapy include direct drug delivery to the diseased organ, targeting to alveolar macrophages harbouring the mycobacteria, reduced risk of systemic toxicity and improved patient compliance. Research efforts have demonstrated the feasibility of various drug delivery systems employing liposomes, polymeric microparticles and nanoparticles to serve as inhalable antitubercular drug carriers. In particular, nanoparticles have emerged as a remarkably useful tool for this purpose. While some researchers have preferred dry powder inhalers, others have emphasized nebulization. Beginning with the respiratory delivery of a single antitubercular drug, it is now possible to deliver multiple drugs simultaneously with a greater therapeutic efficacy. More experience and expertise have been observed with synthetic polymers, nevertheless, the possibility of using natural polymers for inhaled therapy has yet to be explored. Several key issues such as patient education, cost of treatment, stability and large scale production of drug formulations, etc. need to be addressed before antitubercular inhaled therapy finds its way from theory to clinical reality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLGA Nanoparticles in Drug Delivery: The State of the Art;
Bala, I., Hariharan, S., & Kumar, M. R. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i5.20 · Cited by 739
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Self-citationLymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
Videira, M. A., Botelho, M. F., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J. J., & Almeida, A. J. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000054933 · Cited by 213
Cited by
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Polysaccharide-based aerogels—Promising biodegradable carriers for drug delivery systems
García-González, C. A., Alnaief, M., & Smirnova, I. (2011) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2011.06.066 · Cited by 725
Sosnik, A., das Neves, J., & Sarmento, B. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.07.010 · Cited by 487
Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
Paranjpe, M., & Müller-Goymann, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045852 · Cited by 454
Metadata
- Authors
- Pandey, R., & Khuller, G. K.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-01
- Volume
- 55
- Issue
- 4
- Pages
- 430-435
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2155875390
- Cited by
- 188
- References
- 4
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antitubercular inhaled therapy: opportunities, progress and challenges. https://app.cochat.ai/papers/10.1093/jac/dki027
- The paper
- Pandey, R., & Khuller, G. K. (2005). Antitubercular inhaled therapy: opportunities, progress and challenges. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dki027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.